NCT05923515View on ClinicalTrials.gov

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

PHASE1UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

May 1, 2025

Conditions
Malignant Pleural Effusion
Interventions
DRUG

JMKX000197

for injection

Trial Locations (1)

430062

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
collaborator

Zhejiang Hangyu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Jemincare

INDUSTRY

NCT05923515 - A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion | Biotech Hunter | Biotech Hunter